GSK's Bepirovirsen Becomes First Approved Functional Cure for CHB

GSK has secured Japanese approval for (Hibsago) bepirovirsen, an antisense oligonucleotide (ASO) licensed from Ionis Pharmaceuticals, as a functional cure regimen for chronic hepatitis B (CHB) in adults previously treated with nucleos(t)ide analogues for at least six months and meeting viral marker thresholds, making it the first asset globally to achieve this label. The approval rests on the Phase III B-Well 1 and B-Well 2 trials, where bepirovirsen delivered significantly higher functional cure rates than placebo in patients with baseline HBsAg no greater than 3,000 IU/mL, with stronger effect below 1,000 IU/mL.

Bepirovirsen acts by suppressing hepatitis B virus (HBV) DNA replication, lowering circulating HBsAg, and stimulating durable immune response, addressing a disease affecting over 240 million people worldwide with no finite-course cure under standard lifelong antiviral therapy. At an estimated global CHB population of 75 million in China and 1.7 million in the US, even a 20% to 35% functional cure rate in selected low-HBsAg subgroups represents a multi-billion-dollar commercial opportunity, though uptake will hinge on diagnostic stratification and payer willingness to fund a short-course oligonucleotide against cheap generic nucleos(t)ides.

Daily News
BeiGene Advances its First ADC Into Phase III in Ovarian Cancer
2026-09-14
Zelgen's Becomes China's First PD-1×TIGIT BsAb in Phase III for Liver Cancer
2026-09-14
AZ, Amgen TCE+PD-L1 Combo Aces Phase III in Extensive-Stage SCLC
2026-09-11
Lumiere Closes Nine-Figure Pre-A Round for Epigenetic Editing Therapies
2026-09-11
Bayer's Sevabertinib Gains US Approval in First-Line HER2-Mutant NSCLC
2026-09-10
Latest Report
2026 TOP-25 Drug Targets
Details